BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33867843)

  • 1. Wild-type IDH1 inhibits the tumor growth through degrading HIF-α in renal cell carcinoma.
    Chen S; Wang Y; Xiong Y; Peng T; Lu M; Zhang L; Guo Z
    Int J Biol Sci; 2021; 17(5):1250-1262. PubMed ID: 33867843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
    Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
    PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
    Carroll VA; Ashcroft M
    Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
    Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
    Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
    Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
    Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
    Petrella BL; Brinckerhoff CE
    Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma.
    David JM; Owens TA; Inge LJ; Bremner RM; Rajasekaran AK
    Mol Cancer Ther; 2014 Apr; 13(4):788-99. PubMed ID: 24493697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
    Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
    Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
    Gunaratnam L; Morley M; Franovic A; de Paulsen N; Mekhail K; Parolin DA; Nakamura E; Lorimer IA; Lee S
    J Biol Chem; 2003 Nov; 278(45):44966-74. PubMed ID: 12944410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
    Joshi S; Singh AR; Durden DL
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
    Jang Y; Han J; Kim SJ; Kim J; Lee MJ; Jeong S; Ryu MJ; Seo KS; Choi SY; Shong M; Lim K; Heo JY; Kweon GR
    Oncotarget; 2015 Nov; 6(35):38127-38. PubMed ID: 26474388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals.
    Wu TK; Wei CW; Pan YR; Hsu RJ; Wu CY; Yu YL
    Sci Rep; 2019 Mar; 9(1):3207. PubMed ID: 30824757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma.
    An J; Liu H; Magyar CE; Guo Y; Veena MS; Srivatsan ES; Huang J; Rettig MB
    Cancer Res; 2013 Feb; 73(4):1374-85. PubMed ID: 23393199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
    Shang D; Liu Y; Yang P; Chen Y; Tian Y
    Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
    Gong K; Zhang N; Zhang K; Na Y
    Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.